Expert Interview
Discussing EyePoint's EYP-1901 and 4D Molecular Therapeutics' gene therapy, 4D-150 for the treatment of wet-AMD
Ticker(s): EYPT, FDMT, RHHBY, REGNInstitution: UT Southwestern Medical Center
- Professor in the department of ophthalmology who sees 500 patients with AMD
- Director of the Vitreoretinal Fellowship Program and specializes in retina and vitreous diseases, macular degeneration, and diabetic retinopathy.
- Research interest in transplantation of RPE cells, ocular immunology and ocular cell biology
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
